Zhejiang East-Asia Pharmaceutical Co (SHSE:605177) Beta: 1.0525 (As of Jul. 30, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:605177 Zhejiang East-Asia Pharmaceutical Co Ltd SHSE:605177
57 GF Score
Price ¥15.10
GF Value ¥12.42
Valuation Modestly Overvalued
! 8 Warning Signs
View Full Analysis

What is Zhejiang East-Asia Pharmaceutical Co Beta?

Zhejiang East-Asia Pharmaceutical Co SHSE:605177 -1.44% 57 Beta is 1.0525 as of Jul. 30, 2026. GuruFocus rates SHSE:605177 with a GF Score™ of 57/100 and a GF Value™ of ¥12.42 (Modestly Overvalued). The stock has 8 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-30), Zhejiang East-Asia Pharmaceutical Co's Beta is 1.0525.


Zhejiang East-Asia Pharmaceutical Co  (SHSE:605177) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Zhejiang East-Asia Pharmaceutical Co Beta Related Terms


Zhejiang East-Asia Pharmaceutical Co Beta Historical Data

* Premium members only.

The historical data trend for Zhejiang East-Asia Pharmaceutical Co's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zhejiang East-Asia Pharmaceutical Co Beta Chart

Zhejiang East-Asia Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.78 1.04 1.10

Zhejiang East-Asia Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.15 1.08 0.99 1.10 1.10

SHSE:605177 vs VRTX, REGN, RVMD: Beta Comparison

For the Biotechnology subindustry, Zhejiang East-Asia Pharmaceutical Co's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zhejiang East-Asia Pharmaceutical Co Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zhejiang East-Asia Pharmaceutical Co's Beta distribution charts can be found below:

* The bar in red indicates where Zhejiang East-Asia Pharmaceutical Co's Beta falls into.


SHSE:605177
57GF Score
Zhejiang East-Asia Pharmaceutical Co Ltd SHSE:605177
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zhejiang East-Asia Pharmaceutical Co Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 1.0525 mean?
Zhejiang East-Asia Pharmaceutical Co (SHSE:605177) has a Beta of 1.0525 as of Jul. 30, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Zhejiang East-Asia Pharmaceutical Co and its competitors.
Is Zhejiang East-Asia Pharmaceutical Co's Beta too high?
Zhejiang East-Asia Pharmaceutical Co's current Beta is 1.0525. Overall, Zhejiang East-Asia Pharmaceutical Co has a GF Score™ of 57/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Zhejiang East-Asia Pharmaceutical Co's Beta compare to VRTX and REGN?
Zhejiang East-Asia Pharmaceutical Co's Beta of 1.0525 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Zhejiang East-Asia Pharmaceutical Co and its competitors. Zhejiang East-Asia Pharmaceutical Co's current Beta is 1.0525. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang East-Asia Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang East-Asia Pharmaceutical Co (SHSE:605177) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥12.42, compared to a current price of ¥15.10 — trading 21.6% above its estimated fair value. The current Beta is 1.0525. Zhejiang East-Asia Pharmaceutical Co's overall GF Score™ is 57/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Zhejiang East-Asia Pharmaceutical Co (SHSE:605177), the current Beta is 1.0525 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zhejiang East-Asia Pharmaceutical Co (SHSE:605177) Overvalued in 2026?

Based on GuruFocus' analysis, Zhejiang East-Asia Pharmaceutical Co stock appears to be overvalued. The current stock price of ¥15.10 is trading 21.6% above its estimated GF Value™ of ¥12.42. GuruFocus considers Zhejiang East-Asia Pharmaceutical Co to be Modestly Overvalued.

Key valuation signals for SHSE:605177:

  • Beta: 1.0525
  • GF Value™: ¥12.42 vs. price of ¥15.10 (21.6% above fair value)
  • GF Score™: 57/100 with 8 warning signs

No single metric tells the full story. See the SHSE:605177 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Zhejiang East-Asia Pharmaceutical Co Business Description

Address No. 118, Laodong North Road, 23rd Floor, Chamber of Commerce Building, Huangyan District, Zhejiang Province, Taizhou, CHN
Zhejiang East-Asia Pharmaceutical Co Ltd is mainly engaged in the production of bulk pharmaceutical chemicals, tablets, granules and capsules. The company's main products are: Ofloxacin, levofloxacin, loratadine hydrochloride, levofloxacin hydrochloride, trimebutine maleate, ketoconazole, terbinafine hydrochloride, piperazine, ticlazole and so on.
57GF Score

Get the complete analysis for SHSE:605177

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥15.10
Price
¥12.42
GF Value